Of note, patients with HER2+ breast cancer had 2-fold higher serum miR-21 median levels than HDs; whereas patients with HER2− breast cancer had 2.4-fold higher serum miR-19a median levels than HDs (Table S1). Here, ERBB2 is linked to breast carcinoma.